GLOFITAMAB

UNII:	06P3KLK2J8
Formula:
Preferred Substance Name:	GLOFITAMAB

2229047-91-8
ANTI-CD20/CD3 BISPECIFIC MONOCLONAL ANTIBODY RO7082859
COLUMVI
GLOFITAMAB [INN]
GLOFITAMAB [USAN]
GLOFITAMAB [WHO-DD]
GLOFITAMAB-GXBM
IMMUNOGLOBULIN G1 (149-GLUTAMIC ACID,215-GLUTAMIC ACID,461-ALANINE,462-ALANINE,556-GLYCINE,581-CYSTEINE,593-TRYPTOPHAN), ANTI-(HUMAN CD20 ANTIGEN) (HUMAN-MUS MUSCULUS MONOCLONAL RG6026 VH-CH1 FRAGMENT) FUSION PROTEIN WITH PEPTIDE (SYNTHETIC 10-AMINO ACID LINKER) FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN CD3 ANTIGEN .EPSILON.-CHAIN) (HUMAN-MUS MUSCULUS MONOCLONAL RG6026 HEAVY CHAIN VL(.LAMBDA.)-CH1-CH2-CH3), (222->219''')-DISULFIDE WITH IMMUNOGLOBULIN ANTI-(HUMAN CD20 ANTIGEN) (HUMAN-MUS MUSCULUS MONOCLONAL RG6026 .KAPPA.-CHAIN (128-ARGININE,129-LYSINE)) AND (447->232'')-DISULFIDE WITH IMMUNOGLOBULIN ANTI-(HUMAN CD3 ANTIGEN .EPSILON.-CHAIN) (HUMAN-MUS MUSCULUS MONOCLONAL RG6026 LIGHT CHAIN VH-CL(.KAPPA.)), (453->228'), (456->231'), (581->351')-TRIS(DISULFIDE) WITH IMMUNOGLOBULIN G1 (149-GLUTAMIC ACID,215-GLUTAMIC ACID,236-ALANINE,237-ALANINE,331-GLYCINE,351-CYSTEINE,368-SERINE,370-ALANINE,409-VALINE) ANTI-(HUMAN CD20 ANTIGEN) (HUMAN-MUS MUSCULUS MONOCLONAL RG6026 .GAMMA.1-CHAIN) DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL RG6026 .KAPPA.-CHAIN (128-ARGININE,129-LYSINE)
IMMUNOGLOBULIN G1-LAMBDA/KAPPA WITH DOMAIN CROSS-OVER, ANTI-(HOMO SAPIENS MS4A1 (MEMBRANE-SPANNING 4-DOMAINS SUBFAMILY A MEMBER 1, CD20)) AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)) MONOCLONAL ANTIBODY, BISPECIFIC, TRIVALENTGAMMA-LAMBDA HEAVY CHAIN ANTI-MS4A1 AND ANTI-CD3E (VH-CH1-V-LAMBDA-CH1-CH2-CH3) (1-674) (HUMANIZED VH ANTI-MS4A1 (HOMO SAPIENS IGHV1-69*02 (84.7%)-(IGHD)-IGHJ4*01 (100%)) (8.8.12) (1-119)-HOMO SAPIENS IGHG1*01, G1M17 (CH1 K26>E (149), K119>E (215), K120 (216) (120-217), HINGE 1-6 (218-223)) (120-223)-10-MER BIS(TETRAGLYCYL-SERYL) LINKER (224-233)-V-LAMDDA ANTI-CD3E (MUS MUSCULUS IGLV1*01 (81.2%)-IGLJ1*01 (100%)/HOMO SAPIENS IGLV7-46*01 (80.0%)-IGLJ3*01 (100%)) (9.3.9) (234-342)-2-MER BISERYL LINKER (343-344)-HOMO SAPIENS IGHG1*01, G1M17, G1M1 (CH1 K120 (441) (345-442), HINGE 1-15 (443-457), CH2 L1.3>A (461), L1.2>A (462), P114>G (556) (458-567), CH3 S10>C (581), D12 (583), L14 (585), T22>W (593) (568-672), CHS (673-674)) (345-674)), (222-219')-DISULFIDE WITH KAPPA LIGHT CHAIN HUMANIZED ANTI-MS4A1 (1'-219') (HUMANIZED V-KAPPA (HOMO SAPIENS IGKV2-28*01 (87.0%)-IGKJ4*01 (100%)) (11.3.9) (1'-112')-HOMO SAPIENS IGKC*01 (98.1%), E12>R (128), Q13>K (129), KM3 A45.1 (158), V101 (196) (113'-219'))(447-232''')-DISULFIDE WITH VH-C-KAPPA LIGHT CHAIN HUMANIZED ANTI-CD3E (1'''-232''') (HUMANIZED VH (HOMO SAPIENS IGHV3-23*03 (87.0%)-IGKJ6*01 (90.9%)) (8.10.16) (1'''-125''')-HOMO SAPIENS IGKC*01 (99.1%), T1.3>S (127), KM3 A45.1 (171), V101 (209) (126'''-232''')), GAMMA1 HEAVY CHAIN HUMANIZED ANTI-MS4A1 (1''-449'') (HUMANIZED VH (HOMO SAPIENS IGHV1-69*02 (84.7%)-(IGHD)-IGHJ4*01 (100%)) (8.8.12) (1''-119'')-HOMO SAPIENS IGHG1*01, G1M17,1 (CH1 K26>E (149), K119>E (215), K120 (216) (120''-217''), HINGE 1-15 (218''-232''), CH2 L1.3>A (236), L1.2>A (237), P114>G (331) (233''-342''), CH3 Y5>C (351), D12 (358), L14 (360), T22>S (368), L24>A (370), Y86>V (409) (343''-447''), CHS (448''-449'')) (120''-449'')), (222''-219'''')-DISULFIDE WITH KAPPA LIGHT CHAIN HUMANIZED ANTI-MS4A1 (1''''-219'''') (HUMANIZED V-KAPPA (HOMO SAPIENS IGKV2-28*01 (87.0%)-IGKJ4*01 (100%)) (11.3.9) (1''''-112'''')-HOMO SAPIENS IGKC*01 (98.1%), E12>R (128), Q13>K (129), KM3 A45.1 (158), V101 (196) (113''''-219''''))DIMER (453-228'':456-231'':581-351'')-TRISDISULFIDE
RG-6026
RO7082859
RO-7082859

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

GLOFITAMAB

Synonyms and Mappings

Resources